Skip to page content

Daniel E. Furst

Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2011
Development of a Preliminary Scleroderma Gastrointestinal Tract 1.0 Quality of Life Instrument 2007
Reliability, Validity, and Minimally Important Differences of the SF-6D in Systemic Sclerosis 2007
Minimally Important Difference in Diffuse Systemic Sclerosis: Results from the D-penicillamine Study 2006
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a Systemic Sclerosis Clinical Trial 2005